EBMT 2018 | Novel therapies for treating relapsed/refractory ALL
Speaking from the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, Daniel DeAngelo, MD, PhD, of the Dana-Farber Cancer Institute, Boston, MA, outlines the range of novel therapies on the horizon for treating relapsed/refractory acute lymphoblastic leukemia (ALL), including monoclonal antibody-drug conjugates and CAR T-cells.
Transcript (edited for clarity):
So relapsed/refractory acute lymphoblastic leukemia is a very difficult disease to treat. The long-term survival historically has been only about five to eight percent, so clearly new therapies are warranted and fortunately there’s a lot of new development on the rise.
The first drug that was developed and approved is a drug called blinatumomab which is a bi specific antibody where the patient’s t-cells are brought to the cancer cells, the lymphoblasts and and are activated and therefore attack the the cancer. And that’s shown to be very effective as a single agent but still new approaches are warranted.
Inotuzumab is a new drug that was just approved. It is a monoclonal antibody drug conjugate which can be safely given as a single agent or even in combination with remission rates in the 80% range and more than half of those patients achieve a very low level of disease called MRD negativity. And then of course the development of car t-cells so it’s a wide range of options that our patients are going to have and hopefully the improvement for these patients with relapsed and refractory disease.
Get great new content delivered to your inboxSign up